左甲状腺素钠(Levothyroxine Sodium) - 药物靶点：THR_在研适应症：分化型甲状腺癌，粘液性水肿昏迷，垂体功能亢进_专利_临床

概要

基本信息

简介左旋甲状腺素钠是一种小分子药物，作用于甲状腺激素受体，是甲状腺激素受体的激动剂。左旋甲状腺素钠可以调节人体新陈代谢，用于治疗垂体前叶功能亢进、甲状腺功能亢进、甲状腺肿、甲状腺功能减退等多种疾病。其作用机制是增加甲状腺激素的水平，从而调节人体的新陈代谢、心血管系统、中枢神经系统等方面的功能。左旋甲状腺素钠是由AbbVie公司开发的，并于1964年8月7日首次获得批准。

药物类型

小分子化药

别名

LT4、Levothyroxine Sodium Hydrate、Sustained-release T4

+ [31]

靶点

THR

作用方式

激动剂

作用机制

THR激动剂(甲状腺激素受体激动剂)

治疗领域

肿瘤神经系统疾病遗传病与畸形+ [3]

在研适应症

分化型甲状腺癌粘液性水肿昏迷垂体功能亢进+ [6]

非在研适应症-

原研机构

AbbVie, Inc.

在研机构

Azurity Pharmaceuticals, Inc.

AbbVie, Inc.

IBSA Institut Biochimique SA

+ [16]

非在研机构

BERLIN-CHEMIE AG

权益机构

Oliva Therapeutics, LLC

IBSA Institut Biochimique SA

Lannett Co., Inc.

+ [4]

最高研发阶段批准上市

首次获批日期

日本 (1964-08-07),

甲状腺功能减退症

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C15H11I4NNaO4

InChIKeyBRLSOHUOWVCKNI-YDALLXLXSA-N

CAS号55-03-8

查看全部结构式(3)

关联

284

项与左甲状腺素钠相关的临床试验

NCT06790589

/ Not yet recruiting临床2期IIT

COmparison of Two Alternative Thyrotropin Suppression Strategies Among Patients With Advanced Differentiated Cancer of the tHyroid

Most thyroid cancers can be cured with surgery, sometimes with radioactive iodine therapy. However, some patients have cancer that has spread, and some have cancer that comes back after treatment. For those with remaining cancer, lowering TSH levels is recommended. This is because thyroid cancer growth can depend on TSH, so reducing TSH can lower the risk of cancer returning and slow its growth in patients with cancer that can't be surgically removed.
International guidelines recommend keeping TSH levels as low as <0.1 mU/L for patients with advanced thyroid cancer. This advice is based on past studies, but it hasn't been tested in a controlled way. One old study suggested that not lowering TSH enough could lead to more cancer relapses. Another study suggested that lowering TSH more could help prevent cancer from getting worse in high-risk patients. However, a recent study found no link between TSH levels and better outcomes, and the researchers suggested doing a new study to confirm if this practice is truly beneficial.
Lowering TSH levels to <0.1 mU/L using levothyroxine has been the standard of care for treating advanced thyroid cancer for a long time. The researchers would like to investigate whether using levothyroxine to keep TSH levels between 0.1 and 0.5 mU/L is just as safe and effective for cancer treatment as the current recommendation of keeping it below 0.1 mU/L. The researchers also believe this study can help set TSH suppression targets based on cancer type, reducing unnecessary side effects from too much TSH suppression while still achieving the same cancer treatment results.
If the researchers can prove that keeping TSH levels between 0.1 and 0.5 mU/L is just as safe and effective as the standard of care practice, we can change our standard treatment approach. This would help reduce symptoms for our patients.

开始日期2025-12-01

申办/合作机构

AHS Cancer Control Alberta

CTRI/2025/04/084008

/ Not yet recruitingN/AIIT

Impact of thyroid hormone supplementation on postoperative care in patients with subclinical hypothyroidism following on-pump coronary bypass grafting surgery- A randomized controlled trial - Nil

开始日期2025-04-12

申办/合作机构

AIIMS Jodhpur

CTRI/2025/02/080271

/ Not yet recruiting临床2/3期IIT

An Open Labelled Randomized Controlled Trial to evaluate the Efficacy ofVyoshadi Guggul along with Thyroxine in Hypothyroidism - NIL

开始日期2025-02-20

申办/合作机构-

100 项与左甲状腺素钠相关的临床结果

登录后查看更多信息

100 项与左甲状腺素钠相关的转化医学

登录后查看更多信息

100 项与左甲状腺素钠相关的专利（医药）

登录后查看更多信息

61,801

项与左甲状腺素钠相关的文献（医药）

2025-09-01·Comparative Biochemistry and Physiology Part D: Genomics and Proteomics

Non-negative matrix factorization reveals seasonal and sex-specific metabolic tactics in tropical tilapia

Article

作者: Wang, Ching-Wei ; Lin, Ching-Chun ; Furukawa, Fumiya ; Lin, Tzu-Hao ; Wang, Min-Chen ; Tseng, Yung-Che

Understanding metabolic adaptations to seasonal fluctuations in ectothermic organisms is challenging, especially in tropical species where physiological responses are more pronounced than in temperate or polar counterparts. Traditional analytical methods often fail to account for the complex metabolic adjustments that are present in these substantial responses, and the high-dimensional characteristics of metabolomic data complicate the interpretation process when using conventional statistical methods. We utilized Non-negative Matrix Factorization (NMF), an unsupervised machine learning algorithm, to analyze monthly serum metabolomics data from tilapia over a year in order to overcome these limits. A deeper analysis using NMF demonstrated that carbohydrates gained prominence during warmer months, as evidenced by consistently elevated weights of glycolysis intermediates in our quantitative analysis. Furthermore, fatty acids remained an important factor in both warm and cold seasons. Amino acids emerged as particularly versatile metabolites, exhibiting adaptability during seasonal transitions. This flexibility suggests their crucial role in coordinating energy-related adaptations and potentially facilitating epigenetic and reproductive responses to changing environments. Serum aspartate composition during the warm-cold transition indicated sex-specific metabolic strategies, as sexual dimorphism was observed in the seasonal utilization of fatty acids and aspartate. Collectively, NMF objectively assesses the metabolic tactics of tropical fish and reveals latent patterns in real-world metabolic dynamics. Consequently, it possesses the potential to facilitate metabolomics-driven species conservation in response to environmental changes.

2025-08-01·Journal of Pharmaceutical and Biomedical Analysis

Importance of intestinal microflora: Dried toad skin-radix clematidis plasma component analysis and anti-CRC core target study

Article

作者: Wang, Xueyan ; Tang, Dongxin ; Liu, Yang ; Yang, Bing ; Pan, Lijun

The focus of this study is to explore the impact of gut microbiota in different states on the blood components of couplet medications (dried toad skin and radix clematidis) and to identify drug metabolites associated with the gut microbiota. By constructing a pseudo-sterile rat model and combining non-targeted metabolomics with plasma pharmacology, we found that the plasma metabolites of couplet medications underwent significant changes in different gut microbiome environments. The GABA and PGE1 levels in the model group and the model+TCM (traditional chinese medicine) group were both significantly lower than those in the normal+TCM group. When the gut microbiota is imbalanced, drug interventions cannot significantly increase the levels of GABA and PGE1. It further confirmed the correlation between the levels of GABA and PGE1 and the gut microbiota. Based on the results of non-targeted metabolomics, we applied network pharmacology and molecular docking to explore the core targets for colorectal cancer treatment based on gut microbiota. In the end, we identified TNF and PPARG as the two core targets. These research findings provide a possibility for clarifying the molecular mechanisms of couplet medications in the treatment of colorectal cancer. It also laid the foundation for further clarifying the molecular mechanisms of Chanling Paste in the treatment of colorectal cancer.

2025-07-01·Experimental Neurology

Triiodothyronine ameliorates S-ketamine-induced hypomyelination via the PPARα pathway in neonatal rat

Article

作者: Shan, Mengqin ; Feng, Luping ; Tong, Chaoyang ; Zheng, Jijian ; Fu, Xin ; Sun, Liping ; Zhang, Yuxin ; Zhang, Kan

Growing evidence suggests that prolonged or repeated exposure to general anesthesia is associated with white matter alteration in children, which may underlie subsequent cognitive and behavioral abnormalities. Numerous infants undergo anesthesia for surgery each year, so it is imperative to identify the risk factors and find preventative treatment to prevent the effects of early anesthesia exposure. Thyroid hormones play a pivotal role in the process of myelination of white matter. Clinical studies have shown that thyroid hormone levels are decreased after infant surgery, whether thyroid hormone supplementation can prevent long-term toxicity of anesthesia remains to be elucidated. Here we used S-ketamine, an anesthetic drug commonly used in pediatric anesthesia, to investigate changes in thyroid hormones after anesthesia and their effects on myelin development. Our findings showed a significant decrease in thyroid hormones following S-ketamine anesthesia. The administration of triiodothyronine (T3) supplements ameliorated the S-ketamine-induced impairments in motor coordination and myelination. S-ketamine-induced hypothyroidism predominantly affects the differentiation of OPCs to mature oligodendrocytes. Further analysis revealed significant alterations in lipid metabolism, and we observed that S-ketamine inhibited PPARα in OPCs. Treatment with T3 effectively rescued S-ketamine-induced suppression of PPARα. The protective effects of T3 were significantly compromised by the PPARα inhibitor GW6471. The pharmacological activator of PPARα, fenofibrate, rescued the motor coordination deficits and the inhibition of OPC maturation induced by S-ketamine. In conclusion, our study demonstrates that S-ketamine anesthesia induces the decline of thyroid hormone and hypomyelination in neonatal rats. Administration of T3 ameliorates S-ketamine-induced hypomyelination through the PPARα signaling pathway.

122

项与左甲状腺素钠相关的新闻（医药）

2025-04-01

·肿瘤界

《中国肿瘤防治核心科普知识（2025）》——甲状腺癌篇

点击蓝字关注我们《健康中国行动—癌症防治行动实施方案（2023—2030年）》提出，到2030年，癌症防治核心知识知晓率达到80%以上。科学普及，言之有据。为保证肿瘤知识科普的权威性和严谨性，中国抗癌协会依托《中国肿瘤整合诊治指南》即CACA指南，按照疾病“防筛诊治康”的全流程管理体系，连续四年撰写了《中国肿瘤防治核心科普知识》，以CACA指南核心观点为创作源，全面推进我国肿瘤防治权威科普创作和推广。2025年全国肿瘤防治宣传周的主题为“CACA指南，我知你知，全程管理，全息发力”。中国抗癌协会组织专家编写了《中国肿瘤防治核心科普知识（2025）》，覆盖28个瘤种、41个技术，以通俗易懂的形式为大家分享核心知识，摘取部分内容，供参阅使用。问题1：碘摄入与甲状腺癌有何关系？需要吃无碘盐吗？核心观点：碘摄入过多或过少都可能影响甲状腺健康。观点解读：严重缺碘可能增加滤泡癌风险，过量碘（如长期大量吃海带）与乳头状癌风险升高有关。但适量碘摄入（如通过碘盐）通常安全，不会引发癌症。一些人误认为“少碘防癌”，因此购买无碘盐，这种误解源于对碘与甲状腺疾病关系的错误认识。过度限碘反而可能导致甲状腺功能异常，并不能预防癌症。问题2：甲状腺癌的常见症状是什么？早期和晚期有何不同？核心观点：甲状腺癌早期隐匿不易发现，晚期症状明显且多样。观点解读：早期甲状腺癌多无症状，常表现为颈部无痛性肿块，质硬，随吞咽移动。晚期可出现声音嘶哑、吞咽或呼吸困难（肿瘤压迫），甚至远处转移引起的咳嗽或骨痛。问题3：哪些人群是甲状腺癌的高危人群？如何预防？核心观点：有家族史或遗传综合征（如 MEN2）者、童年接受过头颈部辐射者、有慢性甲状腺疾病者及长期接触辐射或化学毒物者。预防措施包括定期超声筛查、避免辐射暴露、保持健康生活方式。问题4：超声在甲状腺癌诊断中的作用是什么？有哪些局限性？核心观点：超声是首选筛查工具，能评估结节大小、形态及高危特征（如微钙化）。但它无法确诊癌症，需结合穿刺活检，且对深部病灶检测有限，结果受操作者经验影响。问题5：穿刺活检如何帮助确诊甲状腺癌？ FNA 结果不确定时为何选基因检测？基因检测有何作用？核心观点：细针穿刺活检（FNAB）通过提取结节细胞进行病理检查，是确诊甲状腺癌的金标准，准确率高，创伤小。若结果不确定（如滤泡性病变），选基因检测是因为它能识别癌相关突变（如 BRAF、RAS），提高诊断准确性。基因检测作用包括辅助诊断（如 BRAF 阳性提示乳头状癌）、评估预后和指导靶向治疗。问题6：甲状腺癌的手术治疗有哪些选择？如何确定？核心观点：手术包括甲状腺叶切除、全甲状腺切除、淋巴结清扫术。观点解读：全切适用于高危病例（如肿瘤大或转移），腺叶切除适合低危单侧小癌。是否清扫淋巴结取决于转移情况，选择依据肿瘤类型和患者状况。问题7：术后放射性碘治疗的目的是什么？哪些患者需要？核心观点：放射性碘治疗用于清除术后残余组织或微小癌灶，降低复发风险。有选择地适用于高危（如转移）或中危（如多灶）患者，低危患者通常无须此疗法。问题8：术后为何需长期服用 LT4 ？正确服药方法是什么？核心观点：术后服用甲状腺激素，例如优甲乐、雷替斯或甲状腺片。一是替代甲状腺激素，维持代谢；二是抑制 TSH，防止癌细胞复发。正确方法：早晨空腹服药，30~60 分钟后方可进食，避免钙剂、铁剂同服，1~2 小时后可吃高蛋白（蛋奶类）食物以免影响 LT4 的吸收；定期验血调整剂量至目标TSH 水平（如 0.1~0.5mIU/L）。问题9：晚期甲状腺癌如何治疗？靶向药物有何副作用？核心观点：晚期（如碘难治或转移）可用靶向药物（如安罗替尼）抑制肿瘤生长，延缓疾病进展。副作用包括高血压、腹泻等，需监测管理。问题10：多学科团队（MDT）与整合医学（HIM）在甲状腺癌治疗中有什么作用？核心观点：MDT 由外科、肿瘤科等专家组成，协作制订个性化治疗方案，确保诊断准确、治疗优化，提升疗效和生活质量。随专业的综合发展会培养与形成整合甲状腺医学专家并引领未来甲状腺癌诊治模式向整合医学发展。问题11：术后如何预防甲状腺癌复发？核心观点：预防复发需定期随访（查 Tg、超声）、坚持 TSH 抑制治疗、保持健康生活，及时处理异常症状（如新肿块）。问题12：甲状腺癌治疗中常见的误区有哪些？误区①：低碘饮食防癌。适量碘才健康，过度限碘有害。误区②：术后无须服药。全切患者需终身服优甲乐。误区③：优甲乐可随意停。停药可能导致甲减或复发。问题13：术后康复期饮食应注意什么？核心观点：饮食富含维生素（蔬果），避免辛辣、油腻食物。少量多餐，保持清淡，促进恢复。碘摄入应适量，不需刻意限制。问题14：甲状腺癌患者术后随访为何重要？核心观点：术后随访（超声、Tg 检查）能早期发现复发或残余病灶，及时干预。随访频率因风险分级而异，低危者每年 1 次，高危者更频繁。问题15：康复期患者如何获得心理支持？核心观点：可通过医生科普、心理咨询或支持团体缓解焦虑。家人陪伴和逐步回归正常生活也有助于增强信心。本文摘录自《中国肿瘤防治核心科普知识（2025）》推荐阅读● 《中国肿瘤防治核心科普知识（2025）》（肺癌）● 《中国肿瘤防治核心科普知识（2025）》（胃癌）● 《中国肿瘤防治核心科普知识（2025）》（肝癌）● 《中国肿瘤防治核心科普知识（2025）》（胰腺癌）● 《中国肿瘤防治核心科普知识（2025）》（免疫治疗）● 《中国肿瘤防治核心科普知识（2025）》（化学治疗）声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：中国抗癌协会科普平台官微编辑：lagertha审核：南星

核酸药物

2025-03-30

·药通社

两款上市四十多年老药，终于迎来过评！

统计每周仿制药一致性评价通过、上市申请、临床申请及审批情况（2025.3.22-2025.3.28）注：周统计截止数据定为每周五，周六周日数据将统计入下周，依此类推本周过评21条（按受理号计算），过评数据少得可怜，首家过评2个品种，是两款已上市四十多年的老药。茶苯海明片，江苏黄河药液首家过评，该品种最早在1982年于国内上市，氯化钙注射液，河北天成药业首家过评，该品种最早在1981年于国内上市，两款都是上市四十多年的老药，终于是过评了。老药过评一定程度上意味着质量的提升，这两款老药尚有多家企业在走审批流程，未来过评的企业会越来越多。本周左甲状腺素钠片又被驳回一家，瑞迪博士未能顺利过评，此品种难度是真的不小，目前仅两家企业顺利过评，Cipla和Uni-Pharma，都是5类过评，没有国内自研，已有多家跨国企业申请被驳回，Dr. Reddys、Mylan、Uni-Pharma、intas制药、Aristo、Cipla均有驳回记录。背后是长沙晶易的公司深圳珐玛易，本周在临床数据上共有6条记录，4条申请临床，2条批准临床，涉及多种外用制剂，这家企业对外用制剂真是全方位布局。↓ 扫码加入群聊 ↓1、仿制药一致性评价过评&驳回情况2、仿制药一致性评价申报情况3、仿制药一致性评价申请&批准临床数据源：摩熵医药投稿/内容沟通：华籍美人（Ww_150525）

一致性评价

2025-03-28

·立国制药

合理用药丨爱咖人士“药”知道：咖啡不能和这些药品使用

随着社会的发展，咖啡已经成为当代上班族的日常饮品。一杯香浓四溢的咖啡，轻松驱散工作的疲乏。咖啡有如此神效，是因为含有咖啡因，它是一种中枢神经系统兴奋剂，能提神醒脑，同时还可以预防心血管疾病、促进胃酸分泌和治疗偏头痛等。但是，大有裨益的咖啡因却和一些药物有相互作用，会导致药效的减弱，甚至发生不良反应。如果您正在使用以下药物，那就暂时和咖啡告别啦！退烧药例如对乙酰氨基酚、布洛芬等。这些退烧药对胃黏膜有刺激作用，咖啡因可以刺激胃酸的分泌，加重胃肠道症状，可能会导致消化性溃疡、糜烂性食管炎等。骨质疏松症治疗药物代表药物阿仑膦酸钠等。一方面，咖啡因降低钙质的吸收。另一方面，增加尿液和肠道中钙的流失。同时降低阿仑膦酸钠的吸收，致使体内钙质进一步流失，加重骨质疏松症状。甲状腺素类药物代表药物左甲状腺素钠片等。甲减患者服用甲状腺素类药物期间，如果同时饮用咖啡，药物的吸收效果会降低，药效减弱，不能有效控制病情。口服避孕药代表药物复方炔诺酮片、复方甲地孕酮片等。咖啡因会影响避孕药的吸收，降低药物有效性。此外，绝大多数口服避孕药会干扰咖啡因的代谢，使咖啡因在体内停留时间延长，导致焦虑、失眠和心悸等。利尿剂代表药物氢氯噻嗪、呋塞米、螺内酯等。咖啡因本身具有利尿作用，如果同时服用利尿剂，容易造成体内钠、钾离子的过度流失，出现电解质紊乱。喹诺酮类抗生素代表药物左氧氟沙星、莫西沙星等。喹诺酮类药物对肝脏中代谢咖啡因的酶活性有抑制作用，减缓咖啡因的代谢，使体内咖啡因浓度升高引起蓄积中毒。呼吸系统类药物代表药物沙丁胺醇、氨茶碱等。此类药物与咖啡同服，起协同作用。可增加对中枢神经系统的兴奋，导致震颤、头痛、心动过速等。镇静催眠药代表药物地西泮、艾司唑仑、阿普唑仑、硝西泮等。咖啡因能引起神经中枢的兴奋，加重失眠症状，阻碍这些药物发挥作用。B族维生素咖啡因可与维生素B1结合，降低其在体内的吸收。也可以刺激肾上腺素的分泌，消耗人体内B族维生素。所以补充B族维生素时尽量不饮用咖啡。咖啡虽好，也“药”注意哦！来源：中国食品药品监管杂志作者：苏州京东方医院初级药师李林育来源：PSM药盾公益、海口药闻编辑：谯英固审核：赵燕宜

CSCO会议

100 项与左甲状腺素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01010	左甲状腺素钠	H03AA01	DB00451

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
分化型甲状腺癌	美国	Mylan Pharmaceuticals, Inc.	2022-04-29
粘液性水肿昏迷	美国	Fresenius Kabi USA LLC	2011-06-24
垂体功能亢进	美国	King Pharmaceuticals Research & Development LLC	2001-05-25
甲状腺功能亢进症	中国	深圳市中联股份合作公司	2000-01-01
甲状腺癌	中国	深圳市中联股份合作公司	2000-01-01
甲状腺肿	日本	ASKA Pharmaceutical Co., Ltd.	1998-02-12
先天性甲状腺功能减退症	韩国	Bukwang Pharmaceutical Co., Ltd.	1974-04-06
粘液水肿	韩国	Bukwang Pharmaceutical Co., Ltd.	1974-04-06
甲状腺功能减退症	日本	Takeda Pharmaceutical Co., Ltd.	1964-08-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
甲状腺功能减退症	临床3期	波多黎各	AbbVie, Inc.	2024-04-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04782856 (CTgov)	临床2期	甲状腺功能减退症 \| 甲状腺肿 \| 甲状腺癌	13	Placebo+Levothyroxine (Single Therapy)	窪鏇範顧淵夢齋鹽鬱衊(遞鹽糧鹹網鬱觸製膚網) = 糧廠鏇製齋鏇積繭製膚廠襯壓願構鬱膚壓顧夢 (繭簾遞艱壓鑰網鏇遞網, 醖艱觸憲窪網獵鬱齋蓋 ~ 構艱範壓夢衊觸醖積遞) 更多	-	2024-06-14
				Liothyronine+Levothyroxine (Combination Therapy)	窪鏇範顧淵夢齋鹽鬱衊(遞鹽糧鹹網鬱觸製膚網) = 鏇膚構襯齋餘憲醖壓遞廠襯壓願構鬱膚壓顧夢 (繭簾遞艱壓鑰網鏇遞網, 鏇構糧憲網網選鏇鬱獵 ~ 鑰淵選淵選網鹽積構顧) 更多
ENDO2024	N/A	先天性甲状腺功能减退症	105	levothyroxine (Transient CH)	繭淵鏇範簾醖積選襯鑰(網夢積鹹淵築鹹衊餘餘) = 願鹽夢餘選鬱衊願壓鬱糧簾艱壓夢構廠糧網憲 (齋夢鏇網鑰淵壓構網鏇 )	-	2024-06-01
				levothyroxine (Permanent CH)	繭淵鏇範簾醖積選襯鑰(網夢積鹹淵築鹹衊餘餘) = 範選鹹製範糧憲觸築範糧簾艱壓夢構廠糧網憲 (齋夢鏇網鑰淵壓構網鏇 )
ENDO2024	N/A	躁郁症 \| 甲状腺毒症	-	Levothyroxine	網網艱廠觸膚觸廠衊觸(膚網遞憲觸衊觸繭鏇廠) = 遞鹽觸鑰夢夢願鹹鏇鏇願齋蓋鏇窪鏇遞選膚築 (鑰製糧蓋廠鏇壓窪願蓋 )	-	2024-06-01
ENDO2024	N/A	甲状腺功能减退症 \| 横纹肌溶解 \| 肾病综合征	-	Levothyroxine	窪鑰艱構網製淵夢範網(餘製蓋範顧獵遞壓遞淵) = Rhabdomyolysis due to hypothyroidism, without an obvious precipitating factor, has been previously reported, but is very rare 膚繭鹹範簾獵網襯鹽範 (鬱遞顧獵願窪積顧製廠 )	-	2024-06-01
				Liothyronine
ENDO2024	N/A	甲状腺功能减退症	45	LT4/LT3 combination therapy	選憲廠構鏇衊廠膚餘願(鏇範鏇積廠鏇醖鹽獵蓋) = 鑰顧範構憲製繭願觸艱鹽鏇齋簾夢夢獵鬱艱鏇 (壓憲蓋夢醖齋齋夢範膚 ) 更多	积极	2024-06-01
				LT4 monotherapy	選憲廠構鏇衊廠膚餘願(鏇範鏇積廠鏇醖鹽獵蓋) = 獵鏇鑰觸鹽製積簾醖構鹽鏇齋簾夢夢獵鬱艱鏇 (壓憲蓋夢醖齋齋夢範膚 ) 更多
ENDO2024	N/A	高甘油三酯血症	-	Lovaza 2gm AM and 2gm PM	淵願積醖觸顧鹹憲艱衊(鹹鏇夢蓋膚夢範鏇窪鏇) = 築築窪簾齋憲積壓製糧繭遞壓範壓網顧窪齋糧 (廠窪網積糧憲襯繭夢蓋 )	-	2024-06-01
				Synthroid 220 mcg IV daily	淵願積醖觸顧鹹憲艱衊(鹹鏇夢蓋膚夢範鏇窪鏇) = 製糧遞糧願製觸襯餘壓繭遞壓範壓網顧窪齋糧 (廠窪網積糧憲襯繭夢蓋 )
ENDO2024	N/A	-	-	Synthroid 150 mcg	網遞憲淵壓觸網憲餘獵(壓繭醖醖餘簾觸襯廠積) = present 積廠繭淵製艱範鏇構鹽 (膚糧膚鏇餘廠齋淵顧鏇 ) 更多	-	2024-06-01
				IV Synthroid 500 mcg weekly infusions
NCT05823012 (Biospace) 人工标引	临床2期	甲状腺功能减退症	46	XP-8121	(網鬱醖餘製齋醖淵製艱) = 壓願鏇鬱夢築積憲鑰憲觸簾衊廠鏇觸鏇膚膚窪 (襯遞壓簾鹽膚窪鏇積鹹 )	积极	2024-05-30
DDW2024	N/A	非酒精性脂肪肝	-	thyroid hormone (Control group (PBS))	顧醖觸鹽製鹽繭鏇網獵(觸範衊艱艱製蓋鬱積襯) = 築鏇鬱鹽網廠選鹽鹽淵廠醖醖淵糧顧餘鬱醖廠 (鹹網鏇窪衊蓋窪淵淵廠 ) 更多	-	2024-05-19
				thyroid hormone (Treatment group (T3))	顧醖觸鹽製鹽繭鏇網獵(觸範衊艱艱製蓋鬱積襯) = 夢選蓋憲積構選遞網鹽廠醖醖淵糧顧餘鬱醖廠 (鹹網鏇窪衊蓋窪淵淵廠 ) 更多
NCT04415658 (CTgov)	临床3期	心脏衰竭 \| 脑死亡	838	Thyroxine (Thyroxine)	壓餘製鏇獵憲鏇鬱製壓(範鹽蓋膚醖鹽膚鹹簾齋) = 窪鬱夢範鏇廠膚壓鑰餘繭製蓋膚憲鏇鑰觸網構 (鏇憲憲築餘糧遞艱鑰鏇, 淵範襯獵獵糧齋艱糧廠 ~ 淵夢網夢艱網壓構鹹夢) 更多	-	2024-01-10
				Saline (Saline Placebo)	壓餘製鏇獵憲鏇鬱製壓(範鹽蓋膚醖鹽膚鹹簾齋) = 廠鹽鏇鹹蓋選遞淵觸鏇繭製蓋膚憲鏇鑰觸網構 (鏇憲憲築餘糧遞艱鑰鏇, 齋襯餘鏇構網鬱簾襯觸 ~ 製繭觸窪憲憲築蓋築醖) 更多